T he Canadian Thoracic Society (CTS) guidelines for the diagnosis and treatment of sleep disordered breathing in adults were developed over the past year. A one-day meeting was held in Montreal, Quebec, on October 28, 2005, just before the annual CTS meeting.The meeting was facilitated by Dr R Davies (Oxford, United Kingdom), and speakers included D Morrison (Halifax, Nova Scotia), J Kimoff (Montreal), J Fleetham (Vancouver, British Columbia), C George (London, Ontario), M Kryger (Winnipeg, Manitoba), P Hanly (Calgary, Alberta), F Hill (Saskatoon, Saskatchewan), D Bradley (Toronto, Ontario), N Ayas (Vancouver), M Fitzpatrick (Kingston, Ontario), F Series (Quebec City, Quebec), K Ferguson (London) and W Tsai (Calgary). This meeting was attended by 28 Canadian physicians with an interest in sleep disordered breathing. A draft of an Executive Summary was developed, and then reviewed and finalized by the CTS Sleep Disordered Breathing Committee at a one-day meeting in Toronto on February 17, 2006 . The Committee members then individually ranked the level of evidence as: grade A -high-quality meta-analysis or single randomized clinical trial (RCT) that had a low risk of bias; grade B -high-quality systematic review of cohort studies or single cohort study with a low risk of bias or extrapolated evidence from high-quality RCTs or RCTs with a risk of bias; grade C -case-control studies or cohort studies with a risk of bias; or grade D -case series, case reports or expert opinion. The Committee members also ranked their agreement with each statement (strongly agree, agree, neutral, disagree or strongly disagree). No statement was included unless at least 90% of the Committee either strongly agreed or agreed with it. At the present time, there is no clear consensus within the field of SDB on the definition of hypopnea; it has also been defined as an abnormal respiratory event lasting at least 10 s with at least a 30% reduction in thoracoabdominal movement or airflow, as compared with baseline, and with at least a 4% desaturation. Polysomnogram reports should clearly indicate which definition of hypopnea the report is based on and ideally should report hypopneas based on both definitions. The severity criteria listed below are based on the first definition of hypopnea, which does not necessarily require a 4% or greater oxygen desaturation. (Level of evidence D) Central apnea/hypopnea event: An event characterized by absent or reduced tidal volume with absent or reduced thoracoabdominal movement, respectively. These events must fulfill criteria A and B (level of evidence D).
I. CLINICAL SYNDROMES AND SEVERITY DEFINITIONS
A. A clear decrease (greater than 50%) from baseline in the amplitude of nasal pressure or respiratory inductance plethysmography (see definition of baseline in the previous OSAHS section) with proportional reductions in ribcage and abdominal movements.
B. The event lasts 10 s or longer.
Severity criteria: There is insufficient evidence to provide criteria for rating severity. Severity criteria: There is insufficient evidence to provide criteria for rating severity.
SHVS
Diagnostic criteria: The individual must fulfill criteria A and B (level of evidence D).
A. One or more of the following: Safety critical occupations or at high risk for a motor vehicle collision: Individuals working with machinery, or employed in hazardous occupations; truck, taxi or bus drivers; railway engineers, airline pilots, air traffic controllers, aircraft mechanics, ship captains and pilots; and car drivers who admit to have fallen asleep while driving within the past two years. (All patients who are considered to be in a safety critical occupation should be told to cease their occupation and/or personal driving until after their medical assessment has been completed and/or appropriate treatment has been established.)
Waiting times: Medical specialist assessment and/or polysomnography should be arranged and completed by the following times after referral (level of evidence D):
• Priority 1 (urgent) cases -within two to four weeks;
• Priority 2 cases -within two months; and
• Priority 3 cases -within six months.
III. DIAGNOSIS
A. Level I (complete laboratory polysomnography) remains the accepted standard for evaluation of SDB and is the test of choice (level of evidence C).
B. Level II (full ambulatory polysomnography) and level III portable monitoring (multichannel cardiorespiratory recording devices) play a useful role in improving access to the diagnosis of SDB (level of evidence C).
C. Level II and III studies can be used to confirm the diagnosis of OSAHS in patients with a moderate to high pretest probability of this disorder, but are of more limited use in patients with comorbid disease and for the diagnosis of other forms of SDB (level of evidence C).
D. Studies using oximetry alone may have a role in the initial assessment of SDB, however, their significant limitations in distinguishing different types of SDB must be fully appreciated before using them to make diagnostic and therapeutic decisions (level of evidence C).
E. The level of experience and training available to interpret the results of sleep monitoring is as important as the type of sleep monitoring (level of evidence D).
F. All sleep monitoring should be conducted with an appropriate quality assurance program and interpreted by a physician trained in the diagnosis of SDB (level of evidence D).
G. Clinical prediction formulas can be used to assess the pretest probability of SDB, and to prioritize patients for evaluation, but are not sufficient to establish a diagnosis (level of evidence C). Treatment may be considered in asymptomatic patients with significant comorbid illness, who work in a safety critical occupation, or who have an apnea/hypopnea index greater than 30 events per hour (level of evidence C).
OSAHS
3. Treatment adherence should be assessed within two to four weeks of initiation of treatment (level of evidence D).
Patients initiated on treatment should undergo
follow-up within three months, by a physician or alternate care provider supervised by a physician, to assess their symptomatic response and adherence to treatment (level of evidence D). E. CPAP therapy 1. Conventional CPAP at a fixed pressure is the primary treatment for patients with OSAHS (level of evidence B).
Long
2. Automatic CPAP is an effective treatment for OSAHS in the absence of comorbid disease, but treatment effectiveness may vary among different machines (level of evidence B).
3. It is unclear if patients benefit from the additional cost of automatic CPAP compared with conventional CPAP (level of evidence B).
4.
A CPAP titration polysomnogram remains the accepted standard to determine optimal CPAP pressure (level of evidence D).
5.
Optimal CPAP pressure can also be determined from the pressure profile from a trial of automatic CPAP, provided there is a careful assessment of recording conditions and a detailed analysis of the pressure profile (level of evidence B). 3. Oral appliances should be fitted by qualified dental practitioners who have undertaken special training in SDB (level of evidence D).
4.
The use of oral appliances should be monitored clinically following initiation of therapy to allow appliance adjustment and assessment of symptoms and side effects (level of evidence D).
Patients should undergo follow-up sleep monitoring
with the oral appliance to ensure effective treatment (level of evidence D).
6. Patients initiated on treatment with an oral appliance should be seen in follow-up by a qualified dental practitioner regularly during the first year and then every year thereafter to monitor treatment adherence, appliance deterioration and oral health (level of evidence D). 
CSAHS/CSBS
1. CSBS is associated with an increased mortality in patients with heart failure (level of evidence B).
2. Optimal medical management is the first-line therapy for CSBS in patients with heart failure (level of evidence C).
3. CPAP and/or oxygen are not recommended as routine therapy for patients with CSBS and heart failure (level of evidence B).
4.
There are no proven therapies for idiopathic CSAHS (level of evidence D).
SHVS
1. All patients with suspected SHVS require urgent referral for specialist assessment and long-term follow-up (level of evidence D).
2. CPAP is the first-line treatment for patients with SHVS when there is associated upper airway obstruction (level of evidence D).
3. Assisted ventilation (bilevel positive airway pressure with or without a timed backup rate, and pressure and volume-cycled ventilators) should be considered if CPAP fails to improve daytime and nocturnal gas exchange (level of evidence D).
Sleep disordered breathing in adults 4. Oxygen should be considered in patients who have persistent hypoxemia despite treatment with CPAP or assisted ventilation (level of evidence D).
5. Treatment should be initiated in an intensive care unit, sleep laboratory, or other closely monitored setting with appropriate support to ensure safe and effective implementation of CPAP, assisted ventilation and oxygen (level of evidence D). 6 . The effectiveness of treatment should be verified with attended polysomnography and arterial blood gas testing to objectively assess the impact on daytime and nocturnal gas exchange (level of evidence D).
